<DOC>
	<DOCNO>NCT02589847</DOCNO>
	<brief_summary>This study evaluate efficacy safety information RBX2660 treatment recurrent Clostridium difficile infection ( CDI ) . Enrolled subject receive one treatment RBX2660 ( microbiota suspension ) .</brief_summary>
	<brief_title>Microbiota Restoration Therapy Recurrent Clostridium Difficile Infection</brief_title>
	<detailed_description>This prospective , multicenter , open-label study assess efficacy safety RBX2660 adjunct antibiotic treatment recurrent CDI . The primary assessment study ( ) ass efficacy absence CDI diarrhea without need retreatment C. difficile anti-infective therapy fecal transplant 56 day completion study treatment RBX2660 ( ii ) safety via assessment adverse event . Patients either ) least two recurrence primary episode ( i.e. , least three episode ) complete least two round standard-of-care oral antibiotic b ) least two episode severe CDI result hospitalization may eligible participate study . Study visit 1- 8-weeks treatment additional follow-up assessment 3,6,12 , 24 month post treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<criteria>â‰¥ 18 year old . Medical record documentation recurrent CDI include positive C. difficile test within 60 day prior enrollment either : ) least two recurrence primary episode complete least two round standardofcare oral antibiotic therapy b ) least two episode severe CDI result hospitalization . Documented history subject 's recurrent CDI control antibiotic even subject currently antibiotic . A positive stool test presence C. difficile within 60 day prior enrollment A known history continue CDI diarrhea despite course antibiotic prescribe CDI treatment . Requires continuous antibiotic therapy condition CDI . Previous successful ( resolution CDI diarrhea ) fecal transplant recurrent CDI &lt; 6 month prior study enrollment . Previous unsuccessful ( recurrent CDI diarrhea unresolved ) fecal transplant . Previous treatment RBX2660 . Diagnosis inflammatory bowel disease ( IBD ) , e.g. , ulcerative colitis , Crohn 's disease , microscopic colitis . Diagnosis irritable bowel syndrome ( IBS ) determine Rome III criterion . History chronic diarrhea . History celiac disease . Disease symptom cause confirmed intestinal pathogen C. difficile . Colostomy . Planned surgery require perioperative antibiotic within 3 month study enrollment . Life expectancy &lt; 12 month . Compromised immune system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Clostridium difficile</keyword>
	<keyword>C diff</keyword>
	<keyword>CDI</keyword>
	<keyword>CDAD</keyword>
	<keyword>Fecal transplant</keyword>
	<keyword>Fecal Microbiota transplant</keyword>
	<keyword>diarrhea</keyword>
	<keyword>FMT</keyword>
	<keyword>microbiota restoration therapy</keyword>
	<keyword>microbiota suspension</keyword>
	<keyword>fecal bacteriotherapy</keyword>
	<keyword>C diff diarrhea</keyword>
</DOC>